Teva Oncology presented two
secondary analyses today featuring omacetaxine mepesuccinate, an
investigational, first-in-class cephalotaxine that functions as a protein
synthesis inhibitor at the American Society of Clinical Oncology Annual
Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that
was submitted to the US Food and Drug Administration as part of a new drug
application (NDA) and was recently accepted for review.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in